Neurological abnormalities specialist Wave Neuroscience said on Thursday that it has closed the brain treatment technology asset purchase agreement with Newport Brain Research Laboratory (NBRL) for an undisclosed amount.
Under the terms of the agreement, Wave Neuroscience purchased substantially all of the assets from the various onshore and offshore holding companies under NBRL.
In conjunction with the acquisition, key NBRL personnel were appointed to new roles at Wave Neuroscience.
Since June, Wave Neuroscience has pledged more than USD500,000 of free treatments to US military members.
According to Wave Neuroscience, its research revolves around the premise that the brain can be treated by non-pharmaceutical and non-surgical means. It offers a personalised treatment platform for addressing neurological abnormalities and has treated more than 7,000 patients using its patented, non-invasive, drug-free MeRT process, which is licensed by a network of independently owned medical facilities.
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
Genflow Biosciences publishes second European patent application for SIRT6 Variant in NASH
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
ACG to invest USD200m in US hard-shell capsule manufacturing